Macquarie Group Ltd. Grows Holdings in Eagle Pharmaceuticals Inc (EGRX)

Macquarie Group Ltd. boosted its holdings in shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 400.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,500 shares of the specialty pharmaceutical company’s stock after buying an additional 1,200 shares during the quarter. Macquarie Group Ltd.’s holdings in Eagle Pharmaceuticals were worth $113,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in EGRX. Itau Unibanco Holding S.A. acquired a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $108,000. Meeder Asset Management Inc. increased its position in shares of Eagle Pharmaceuticals by 232.6% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,866 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,305 shares during the last quarter. Piedmont Investment Advisors LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter valued at approximately $150,000. US Bancorp DE increased its position in shares of Eagle Pharmaceuticals by 191.9% in the 2nd quarter. US Bancorp DE now owns 2,767 shares of the specialty pharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,819 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 1st quarter valued at approximately $212,000.

Shares of NASDAQ:EGRX opened at $60.14 on Friday. Eagle Pharmaceuticals Inc has a 52 week low of $48.84 and a 52 week high of $85.66. The company has a current ratio of 4.22, a quick ratio of 4.09 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 17.85 and a beta of 1.32.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating the Zacks’ consensus estimate of $0.80 by $0.15. The company had revenue of $59.30 million for the quarter, compared to the consensus estimate of $51.78 million. Eagle Pharmaceuticals had a net margin of 13.81% and a return on equity of 19.71%. On average, research analysts forecast that Eagle Pharmaceuticals Inc will post 2.15 earnings per share for the current year.

A number of equities research analysts have commented on EGRX shares. increased their price objective on shares of Eagle Pharmaceuticals to $119.00 and gave the company a “buy” rating in a research report on Tuesday, July 3rd. Piper Jaffray Companies set a $86.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 24th. BidaskClub downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, September 18th. Cantor Fitzgerald set a $81.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Finally, TheStreet raised shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $86.50.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Featured Article: Balance Sheet

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply